Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madame Bioscience PCL's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Madame Bioscience PCL's 5-Year Yield-on-Cost % or its related term are showing as below:
BKK:MADAME's 5-Year Yield-on-Cost % is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 3.38 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Madame Bioscience PCL 5-Year Yield-on-Cost % Related Terms
BKK:MADAME vs KHC, GIS: 5-Year Yield-on-Cost % Comparison
For the Packaged Foods subindustry, Madame Bioscience PCL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madame Bioscience PCL 5-Year Yield-on-Cost % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Madame Bioscience PCL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Madame Bioscience PCL's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Madame Bioscience PCL (BKK:MADAME) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Madame Bioscience PCL and its competitors. According to the industry distribution chart, Madame Bioscience PCL ranks #999999 out of 1152 companies in the Consumer Packaged Goods industry.
Is Madame Bioscience PCL's 5-Year Yield-on-Cost % too high?
Madame Bioscience PCL's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Madame Bioscience PCL ranks #999999 out of 1152 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Madame Bioscience PCL has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Madame Bioscience PCL's 5-Year Yield-on-Cost % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Madame Bioscience PCL ranks #999999 out of 1152 companies for 5-Year Yield-on-Cost %. This places Madame Bioscience PCL in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Consumer Packaged Goods company?
The median 5-Year Yield-on-Cost % among Consumer Packaged Goods companies is 3.38, based on 1,152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Madame Bioscience PCL and its competitors. For the Consumer Packaged Goods industry, the median 5-Year Yield-on-Cost % is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madame Bioscience PCL's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madame Bioscience PCL stock overvalued right now?
Based on GuruFocus' analysis, Madame Bioscience PCL (BKK:MADAME) is currently considered Significantly Overvalued. The stock's GF Value™ is ฿0.63, compared to a current price of ฿1.08 — trading 71.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Madame Bioscience PCL's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Madame Bioscience PCL (BKK:MADAME), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Madame Bioscience PCL (BKK:MADAME) Overvalued in 2026?
Based on GuruFocus' analysis, Madame Bioscience PCL stock appears to be overvalued.
The current stock price of ฿1.08 is trading 71.4% above its estimated GF Value™ of ฿0.63.
GuruFocus considers Madame Bioscience PCL to be Significantly Overvalued.
Key valuation signals for BKK:MADAME:
5-Year Yield-on-Cost %: 0.00
GF Value™: ฿0.63 vs. price of ฿1.08 (71.4% above fair value)
No single metric tells the full story. See the BKK:MADAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Madame Bioscience PCL is engaged in the segments of the Packaging business, Food business, Retail sales of cosmetics, and Other businesses. Its activities include the manufacturing and selling of plastic packaging, restaurant business, advertising rental service in the gas station and manufacturing and selling of dried fruits, among others. The group derives a majority of its revenue from the Food business. The firm's product portfolio includes Ready meals, Frozen food, value-added seafood and vegetables, Flexible packaging, and PET Bottles.
31GF Score
Get the complete analysis for BKK:MADAME
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:MADAME has been successfully added to your 
